Changing Landscape of Diagnosis and Personalized Therapies for Acute Myeloid Leukemia – Live

Description

Program Description

---

Click to Go to the Event Registration

AML is the most common acute leukemia, with significant chromosomal translocations and mutations in the genes involved in hematopoietic proliferation and differentiation, resulting in the accumulation of poorly differentiated myeloid cells. AML is a highly heterogeneous disease with favorable, intermediate, and adverse-risk groups based on their cytogenetic profile. The prognosis within these categories varies widely. Identifying recurrent genetic mutations, such as FLT3-ITD, NMP1, and CEBPA, has helped refine individual prognosis and guide management. The selection of patients based on cytogenetic, molecular genetic markers, and human leukocyte antigen (HLA) testing and treatment with CPX-351, IDH1/2, FLT3, BCl-2, CD33, and Hedgehog pathway targeted agents, and HCT is the focus of the virtual live and enduring webcast.

Agenda

---

• Overview of cytogenetic mutations, disease classification, and risk stratification recommendations in acute myeloid leukemia (AML) – Richard M. Stone, MD
• Discuss the personalized treatment options with CPX-351, IDH1/2, FLT3, CD33, and Hedgehog pathway targeted agents in genomic subgroups of AML – Harry P. Erba, MD, PhD

Intended Audience

---

Hematologists/oncologists, nurse practitioners, and physician assistants involved in diagnosing and treating patients with acute myeloid leukemia (AML).

Commercial Supporter

---

Supported by an educational grant from Daiichi Sankyo, Inc.